08.25.26 -- Pharma Outsourcing Is Evolving. Cold Chain Monitoring Shows Why

Variability reduction programs improve biomanufacturing by controlling raw‑material complexity, optimizing critical attributes, and boosting productivity through data‑driven partnerships.

Rapid mycoplasma testing enhances cell and gene therapy safety by reducing turnaround time, minimizing sample needs, and delivering reliable contamination detection across diverse matrices.

Learn how to select high-quality raw materials for cell-based manufacturing in this exploration of the criticality of raw materials, from preclinical development to commercialization. 

To ensure the commercial success of cell therapies, developers must adopt innovative manufacturing and QC technologies that reduce COGS while enhancing scalability, quality, and clinical outcomes.

High-quality phosphoramidites are key to oligonucleotide therapies. Learn how data-driven optimization boosts purity, streamlines manufacturing, speeds scale-up, and supports commercialization.

Cryopreservation eliminates rigid timelines by decoupling collection from production, providing the flexibility needed to optimize facility use and stabilize advanced therapy supply chains.

Personalized cancer vaccines face a DNA production bottleneck. Synthetic approaches speed timelines, boost consistency, and simplify workflows to deliver individualized therapies faster.

CDMOs are modernizing IT validation by adopting risk-based, lifecycle approaches, digital tools, and continuous assurance models to improve compliance, efficiency, scalability, and data integrity.

Low AAV productivity and a lack of platform processes continue to be challenges driving AAV production costs up. Explore a robust and scalable suspension manufacturing platform for AAV production.

Uncover an automated, closed cell‑therapy manufacturing system that boosts consistency, scalability, and quality while addressing donor variability and optimizing key process and performance parameters.

Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.

View highlights of in-house plasmid manufacturing, expanded commercialization development, and cost reduction in gene therapy manufacturing.

See how a continuous manufacturing platform streamlines production to days, uses real-time quality control, and dramatically cuts costs to accelerate access to new therapies.

Accelerate your mRNA development and strengthen your response to emerging health threats with next-generation, cell-free DNA template solutions designed for speed, quality, and reliability.